Present-day anthelmintics and perspectives on future new targets.

作者: Amira Taman , Manar Azab

DOI: 10.1007/S00436-014-3969-7

关键词:

摘要: In absence of vaccines for the majority helminths, chemotherapy is still mainstay controlling human helminthiases. However, a limited number drugs are available in market to combat parasitic helminths human. Besides, development and spread drug resistance have declined use most currently anthelmintics. Clearly, availability new anthelmintic agents will be essential next few years. More research into mechanisms actions their targets eminent discovery novel agents. Recent techniques mostly rely on mechanism-based screening compounds heterologously expressed bacterial, mammalian or yeast cells. Although this usually successful approach, it money- time-consuming; meanwhile, pharmaceutical companies prefer tested target that chosen based basic research. The nervous system site action several chemotherapeutics including pesticides antinematode drugs; accordingly, continues promising target. advances exploring helminths' system, neurotransmitters receptors paved way potential targeting its components.

参考文章(83)
Fadi F Hamdan, Mark Abramovitz, Aisha Mousa, Jinling Xie, Yves Durocher, Paula Ribeiro, None, A novel Schistosoma mansoni G protein-coupled receptor is responsive to histamine Molecular and Biochemical Parasitology. ,vol. 119, pp. 75- 86 ,(2002) , 10.1016/S0166-6851(01)00400-5
Jennifer Keiser, Jürg Utzinger, Artemisinins and synthetic trioxolanes in the treatment of helminth infections Current Opinion in Infectious Diseases. ,vol. 20, pp. 605- 612 ,(2007) , 10.1097/QCO.0B013E3282F19EC4
Samar N. El-Beshbishi, Amira Taman, Mohamed El-Malky, Manar S. Azab, Amira K. El-Hawary, Dina A. El-Tantawy, First insight into the effect of single oral dose therapy with artemisinin-naphthoquine phosphate combination in a mouse model of Schistosoma mansoni infection. International Journal for Parasitology. ,vol. 43, pp. 521- 530 ,(2013) , 10.1016/J.IJPARA.2013.01.007
Fouad El-Shehabi, Jon J. Vermeire, Timothy P. Yoshino, Paula Ribeiro, Developmental expression analysis and immunolocalization of a biogenic amine receptor in Schistosoma mansoni. Experimental Parasitology. ,vol. 122, pp. 17- 27 ,(2009) , 10.1016/J.EXPPARA.2009.01.001
Jennifer Keiser, Jürg Utzinger, Advances in the discovery and development of trematocidal drugs Expert Opinion on Drug Discovery. ,vol. 2, ,(2007) , 10.1517/17460441.2.S1.S9
Samar N. El-Beshbishi, Amira Taman, Mohamed El-Malky, Manar S. Azab, Amira K. El-Hawary, Dina A. El-Tantawy, In vivo effect of single oral dose of artemether against early juvenile stages of Schistosoma mansoni Egyptian strain. Experimental Parasitology. ,vol. 135, pp. 240- 245 ,(2013) , 10.1016/J.EXPPARA.2013.07.006
NR de Silva, JLGJ Sirisena, DPS Gunasekera, MM Ismail, HJ de Silva, Effect of mebendazole therapy during pregnancy on birth outcome. The Lancet. ,vol. 353, pp. 1145- 1149 ,(1999) , 10.1016/S0140-6736(98)06308-9
Livia Pica-Mattoccia, Donato Cioli, Sex- and stage-related sensitivity of Schistosoma mansoni to in vivo and in vitro praziquantel treatment. International Journal for Parasitology. ,vol. 34, pp. 527- 533 ,(2004) , 10.1016/J.IJPARA.2003.12.003
John O Gyapong, Vasanthapuram Kumaraswami, Gautam Biswas, Eric A Ottesen, Treatment strategies underpinning the global programme to eliminate lymphatic filariasis. Expert Opinion on Pharmacotherapy. ,vol. 6, pp. 179- 200 ,(2005) , 10.1517/14656566.6.2.179
Charles D Mackenzie, Timothy G Geary, Flubendazole: a candidate macrofilaricide for lymphatic filariasis and onchocerciasis field programs Expert Review of Anti-infective Therapy. ,vol. 9, pp. 497- 501 ,(2011) , 10.1586/ERI.11.30